MAGE-A3-specific anticancer immunotherapy in the clinical practice.
Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS15, a multicomponent immunostimulant, was found to elicit robust antigen-specific immune responses.
GlaxoSmithKline Biologicals; Rixensart, Belgium.
Vincent G
VG
Brichard
Quentin
Q
Godechal
MAGE-A3; biomarkers; cancer; immunization; immunotherapy